Emil Kakkis, M.D., Ph.D.: key facts
- Kind of voice
- Academic
- Role
- CEO of Ultragenyx
- Quoted on
- Rare diseases
- Press citations held
- 1
- Most recently quoted
- 29 Sept 2026
“We recognize the profound urgency of making this therapy available to families, and our focus now is on supporting timely access in the U.S. as we work closely with treatment centers and payers to support families on the gene therapy treatment journey.”
Where Emil Kakkis, M.D., Ph.D. has been quoted
- FDA approves Ultragenyx’s gene therapy Fayuvi for rare neurodegenerative disorderfiercepharma.com · 29 Sept 2026
Professors, researchers and think-tank analysts quoted on the strength of their research rather than a clinical role. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 29 Sept 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.